These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 30015528)

  • 1. Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II Trials.
    Goto H; Zako M; Namba K; Hashida N; Kaburaki T; Miyazaki M; Sonoda KH; Abe T; Mizuki N; Kamoi K; Brézin AP; Dick AD; Jaffe GJ; Nguyen QD; Inomata N; Kwatra NV; Camez A; Song AP; Kron M; Tari S; Ohno S
    Ocul Immunol Inflamm; 2019; 27(1):40-50. PubMed ID: 30015528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.
    Nguyen QD; Merrill PT; Jaffe GJ; Dick AD; Kurup SK; Sheppard J; Schlaen A; Pavesio C; Cimino L; Van Calster J; Camez AA; Kwatra NV; Song AP; Kron M; Tari S; Brézin AP
    Lancet; 2016 Sep; 388(10050):1183-92. PubMed ID: 27542302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study: VISUAL III.
    Suhler EB; Adán A; Brézin AP; Fortin E; Goto H; Jaffe GJ; Kaburaki T; Kramer M; Lim LL; Muccioli C; Nguyen QD; Van Calster J; Cimino L; Kron M; Song AP; Liu J; Pathai S; Camez A; Schlaen A; van Velthoven MEJ; Vitale AT; Zierhut M; Tari S; Dick AD
    Ophthalmology; 2018 Jul; 125(7):1075-1087. PubMed ID: 29429764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab for the treatment of refractory active and inactive non-infectious uveitis.
    Lee JT; Yates WB; Rogers S; Wakefield D; McCluskey P; Lim LL
    Br J Ophthalmol; 2018 Dec; 102(12):1672-1678. PubMed ID: 29459430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
    Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD
    JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Adalimumab in Non-Infectious Uveitis Across Different Etiologies: A Post Hoc Analysis of the VISUAL I and VISUAL II Trials.
    Merrill PT; Vitale A; Zierhut M; Goto H; Kron M; Song AP; Pathai S; Fortin E
    Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1569-1575. PubMed ID: 32469621
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Suhler EB; Jaffe GJ; Fortin E; Lim LL; Merrill PT; Dick AD; Brezin AP; Nguyen QD; Thorne JE; Van Calster J; Cimino L; Adan A; Goto H; Kaburaki T; Kramer M; Vitale AT; Kron M; Song AP; Liu J; Pathai S; Douglas KM; Schlaen A; Muccioli C; Van Velthoven MEJ; Zierhut M; Rosenbaum JT
    Ophthalmology; 2021 Jun; 128(6):899-909. PubMed ID: 33157077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adalimumab in Patients with Active Noninfectious Uveitis.
    Jaffe GJ; Dick AD; Brézin AP; Nguyen QD; Thorne JE; Kestelyn P; Barisani-Asenbauer T; Franco P; Heiligenhaus A; Scales D; Chu DS; Camez A; Kwatra NV; Song AP; Kron M; Tari S; Suhler EB
    N Engl J Med; 2016 Sep; 375(10):932-43. PubMed ID: 27602665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Experience with Anti-tumor Necrosis factor - α Therapy in the Treatment of Refractory, Non-infectious Intermediate, Posterior, and Panuveitis.
    Corredores Dieb J; Vofo B; Amer R
    Ocul Immunol Inflamm; 2024 Aug; 32(6):932-939. PubMed ID: 36538811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab: A Review in Non-Infectious Non-Anterior Uveitis.
    Hoy SM
    BioDrugs; 2017 Apr; 31(2):135-142. PubMed ID: 28229433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Systemic biological treatment in ophthalmology].
    Benyó F; Farkas A; Horváth H; Nagy ZZ; Szepessy Z
    Orv Hetil; 2019 Nov; 160(44):1744-1750. PubMed ID: 31657252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Al-Janabi A; El Nokrashy A; Sharief L; Nagendran V; Lightman S; Tomkins-Netzer O
    Ophthalmology; 2020 Mar; 127(3):410-416. PubMed ID: 31607412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.
    Suhler EB; Thorne JE; Mittal M; Betts KA; Tari S; Camez A; Bao Y; Joshi A
    Ophthalmology; 2017 Dec; 124(12):1799-1807. PubMed ID: 28689898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of adalimumab in refractory non-infectious childhood chronic uveitis: efficacy in ocular disease--a case cohort interventional study.
    Sen ES; Sharma S; Hinchcliffe A; Dick AD; Ramanan AV
    Rheumatology (Oxford); 2012 Dec; 51(12):2199-203. PubMed ID: 22923752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Controlled Study to Evaluate the Efficacy of Adalimumab in Patients with Different Forms of Refractory Uveitis.
    Mackensen F; Heinz C; Jakob E; Grewing V; Lorenz HM; Heiligenhaus A; Max R; Becker MD
    Ocul Immunol Inflamm; 2018; 26(7):1015-1022. PubMed ID: 29286865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial.
    Suhler EB; Lowder CY; Goldstein DA; Giles T; Lauer AK; Kurz PA; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Tessler HH; Smith JR; Rosenbaum JT
    Br J Ophthalmol; 2013 Apr; 97(4):481-6. PubMed ID: 23376607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Anti-TNF-α Therapy for the Treatment of Non-infectious Uveitis: A Retrospective Study of 21 Patients.
    Mercier AE; Ribeiro E; Korobelnik JF; Delyfer MN; Rougier MB
    Ocul Immunol Inflamm; 2018; 26(3):477-484. PubMed ID: 27775458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab in Elderly Patients with Non-Infectious Uveitis. Safety and Efficacy.
    Moll-Udina A; Miguel Escuder L; Hernanz I; Llorenç V; Fonollosa A; Cordero Coma M; Sainz de la Maza M; Espinosa G; González Guijarro JJ; Lopez Lopez F; Alba-Linero C; Hernández M; Martínez Costa L; Celdrán Vivancos D; Giralt L; Artaraz J; Soler Bartrina P; Jódar Márquez M; García de Vicuña R; Esquinas C; Adán A
    Ocul Immunol Inflamm; 2021 Nov; 29(7-8):1591-1598. PubMed ID: 32657649
    [No Abstract]   [Full Text] [Related]  

  • 19. Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study.
    Hamam RN; Barikian AW; Antonios RS; Abdulaal MR; Alameddine RM; El Mollayess G; Mansour AM
    Ocul Immunol Inflamm; 2016 Jun; 24(3):319-26. PubMed ID: 25549063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of pediatric uveitis with adalimumab: the MERSI experience.
    Castiblanco C; Meese H; Foster CS
    J AAPOS; 2016 Apr; 20(2):145-7. PubMed ID: 27079596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.